Signals
5Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Insomnia comorbid with mental health conditions acquires structured therapy options
Daridorexant maturity, cognitive-behavioural therapy for insomnia (CBT-I) digital expansion, and integrated mental-health-and-insomnia treatment models are reshaping comorbid insomnia care.
OCD and intractable-condition options widen
Deep brain stimulation, transcranial magnetic stimulation, and emerging psychedelic-assisted therapy are all reaching into refractory OCD.
Adult ADHD prescribing patterns are being reshaped by stimulant supply normalisation
The acute stimulant supply shortages that characterised 2022 to 2024 in adult ADHD are normalising. Prescribing patterns are stabilising at higher absolute levels than pre-shortage, with implications for both the established stimulant class and the non-stimulant pipeline.
Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia
Real-world uptake of long-acting injectable (LAI) antipsychotics in schizophrenia is well below the eligible-population estimate across major markets, despite strong adherence and outcome benefits. The drivers are access infrastructure, prescriber inertia, and patient-pathway operational complexity.